Your browser doesn't support javascript.
loading
Exposure time versus cytotoxicity for anticancer agents.
Evans, David M; Fang, Jianwen; Silvers, Thomas; Delosh, Rene; Laudeman, Julie; Ogle, Chad; Reinhart, Russell; Selby, Michael; Bowles, Lori; Connelly, John; Harris, Erik; Krushkal, Julia; Rubinstein, Larry; Doroshow, James H; Teicher, Beverly A.
Afiliação
  • Evans DM; Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
  • Fang J; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, 20852, USA.
  • Silvers T; Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
  • Delosh R; Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
  • Laudeman J; Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
  • Ogle C; Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
  • Reinhart R; Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
  • Selby M; Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
  • Bowles L; Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
  • Connelly J; Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
  • Harris E; Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
  • Krushkal J; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, 20852, USA.
  • Rubinstein L; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, 20852, USA.
  • Doroshow JH; Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, 20852, USA.
  • Teicher BA; Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, 20852, USA. Beverly.Teicher@nih.gov.
Cancer Chemother Pharmacol ; 84(2): 359-371, 2019 08.
Article em En | MEDLINE | ID: mdl-31102023
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cancer Chemother Pharmacol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Alemanha
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cancer Chemother Pharmacol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Alemanha